Description for experts
Venetoclax in addition to Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)
Description for laymen
Venetoclax in addition to Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)
JSON Data
{
"short_title": "GMALL-BLIVEN",
"data_mode": "910",
"data_mode_number": "000000024",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "rezidiv_haema",
"ctgov_number": null,
"eudract_number": "2021-001384-25",
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": "Venetoclax zus\u00e4tzliche zur Blinatumomab-Therapie bei rezidivierter/refrakt\u00e4rer BCP-ALL",
"description_laie_en": "Venetoclax in addition to Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)",
"description_expert_de": "Venetoclax zus\u00e4tzliche zur Blinatumomab-Therapie bei rezidivierter/refrakt\u00e4rer BCP-ALL",
"description_expert_en": "Venetoclax in addition to Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 31
}
